Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan

Table 2

The major outcomes of EAL-10 and EAL-14 eradication therapy.

	Eradication rate
	EAL-10 (𝑛=100)	EAL-14 (𝑛=100)	𝑃 value
Intention-to-treat	68% (68/100)	86% (86/100)	0.002
Per-protocol	75.6% (68/90)	92.5% (86/93)	0.002
Adverse event	11% (11/100)	16% (16/100)	0.301
Compliance	100% (100/100)	99% (99/100)	1.000

EAL-10: esomeprazole/amoxicillin/levofloxacin triple therapy × 10 days and EAL-14: esomeprazole/amoxicillin/levofloxacin triple therapy × 14 days.